Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis

BACKGROUND: Vorinostat, a histone deacetylase (HDAC) inhibitor, was investigated in combination with capecitabine plus cisplatin (XP) as a first-line chemotherapy for patients with unresectable or metastatic gastric cancer (GC). METHODS: Eligible patients received 400 mg vorinostat once daily on day...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Changhoon, Ryu, Min-Hee, Na, Young-Soon, Ryoo, Baek-Yeol, Lee, Chae-Won, Kang, Yoon-Koo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891506/
https://www.ncbi.nlm.nih.gov/pubmed/27172248
http://dx.doi.org/10.1038/bjc.2016.125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891506/
https://www.ncbi.nlm.nih.gov/pubmed/27172248
http://dx.doi.org/10.1038/bjc.2016.125

Ejemplares similares